Quick Answer
Arcutis Biotherapeutics, Inc. reported Total Revenue of $376.07 million for fiscal year 2025.
Arcutis Biotherapeutics, Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $376.07M | +91.3% |
| 2024 | $196.54M | +229.7% |
| 2023 | $59.61M | +1517.1% |
| 2022 | $3.69M | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $99.22M | +121.7% | +21.7% |
| June 30, 2025 | $81.50M | +164.1% | +23.8% |
| March 31, 2025 | $65.85M | +32.8% | +47.1% |
| September 30, 2024 | $44.76M | +17.4% | +45.0% |
| June 30, 2024 | $30.86M | +494.6% | -37.7% |
| March 31, 2024 | $49.57M | +1682.4% | +30.1% |
| September 30, 2023 | $38.11M | — | +634.3% |
| June 30, 2023 | $5.19M | — | +86.6% |
- Arcutis Biotherapeutics, Inc. showed an increase of +91.3% in Total Revenue compared to the prior fiscal year.
- Over the 2022–2025 period, Arcutis Biotherapeutics, Inc.’s total revenue has grown by 10102.7% (from $3.69 million to $376.07 million).
- The most recent figure is from Arcutis Biotherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: